WO2022020891A1 - Méthodes de prophylaxie et de traitement du coronavirus - Google Patents

Méthodes de prophylaxie et de traitement du coronavirus Download PDF

Info

Publication number
WO2022020891A1
WO2022020891A1 PCT/AU2021/050819 AU2021050819W WO2022020891A1 WO 2022020891 A1 WO2022020891 A1 WO 2022020891A1 AU 2021050819 W AU2021050819 W AU 2021050819W WO 2022020891 A1 WO2022020891 A1 WO 2022020891A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
group
alkyl
starting material
pyrimidine
Prior art date
Application number
PCT/AU2021/050819
Other languages
English (en)
Inventor
Albert George Frauman
Original Assignee
Esfam Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902633A external-priority patent/AU2020902633A0/en
Application filed by Esfam Biotech Pty Ltd filed Critical Esfam Biotech Pty Ltd
Publication of WO2022020891A1 publication Critical patent/WO2022020891A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La présente invention concerne une méthode de prophylaxie ou de traitement d'une infection par le coronavirus chez un sujet, la méthode comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule (I) :
PCT/AU2021/050819 2020-07-27 2021-07-27 Méthodes de prophylaxie et de traitement du coronavirus WO2022020891A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2020902633 2020-07-27
AU2020902633A AU2020902633A0 (en) 2020-07-27 Methods of prophylaxis and treatment of corona virus
AU2020903002A AU2020903002A0 (en) 2020-08-21 Methods of prophylaxis and treatment of corona virus
AU2020903002 2020-08-21

Publications (1)

Publication Number Publication Date
WO2022020891A1 true WO2022020891A1 (fr) 2022-02-03

Family

ID=80037926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2021/050819 WO2022020891A1 (fr) 2020-07-27 2021-07-27 Méthodes de prophylaxie et de traitement du coronavirus

Country Status (1)

Country Link
WO (1) WO2022020891A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134035A1 (fr) * 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. DÉRIVÉS D'AMIDE PYRIMIDINE ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α] À SUBSTITUTION ALPHA
WO2009123986A1 (fr) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 de régulation de signal d'apoptose
WO2016174079A1 (fr) * 2015-04-28 2016-11-03 Janssen Sciences Ireland Uc Composés de pyrazolo- et triazolo-pyrimidine antiviraux du virus respiratoire syncytial (vrs)
WO2018145080A1 (fr) * 2017-02-06 2018-08-09 Case Western Reserve University Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134035A1 (fr) * 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. DÉRIVÉS D'AMIDE PYRIMIDINE ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α] À SUBSTITUTION ALPHA
WO2009123986A1 (fr) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase 1 de régulation de signal d'apoptose
WO2016174079A1 (fr) * 2015-04-28 2016-11-03 Janssen Sciences Ireland Uc Composés de pyrazolo- et triazolo-pyrimidine antiviraux du virus respiratoire syncytial (vrs)
WO2018145080A1 (fr) * 2017-02-06 2018-08-09 Case Western Reserve University Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SELEY-RADTKE KATHERINE L., YATES MARY K.: "The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 154, 1 June 2018 (2018-06-01), NL , pages 66 - 86, XP055900662, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2018.04.004 *

Similar Documents

Publication Publication Date Title
CN113544128B (zh) Kras-g12c抑制剂
JP5097701B2 (ja) Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体
JP3447292B2 (ja) イミダゾピリジン及び胃腸の疾病の治療のためのその使用
KR20030008151A (ko) 이미다조피리딘 및 이미다조피리미딘 항바이러스제
CN111943932B (zh) 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
TW201542567A (zh) 用於增進先天性免疫反應之化合物及方法
CN112521386B (zh) 具有抗病毒作用的多环吡啶酮化合物及其药物组合和用途
EP0806418A2 (fr) Composés de pyrimidine et agent anti-rotavirus
JP5404607B2 (ja) 抗ｒｎａウイルス作用を有するアニリン誘導体
WO2021248909A1 (fr) Composé d'isoquinoléine, son procédé de fabrication et son utilisation
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
AU2017373758B2 (en) Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
KR20200118145A (ko) 테트라히드로이소퀴놀린계 화합물, 이의 제조 방법, 테트라히드로이소퀴놀린계 화합물을 포함하는 약물 조성물 및 이의 용도
TW202334163A (zh) 離胺酸乙醯基轉移酶6a (kat6a)抑制劑及其用途
CN110003204A (zh) 一种bet蛋白抑制剂、其制备方法及用途
WO2021178362A1 (fr) Modulateurs d'assemblage de capside de l'hépatite b
WO2022020891A1 (fr) Méthodes de prophylaxie et de traitement du coronavirus
WO2022020889A1 (fr) Méthode de traitement du cytomégalovirus
CN114478511B (zh) 苯并恶唑类化合物及其制备方法、药物组合物和应用
SK197A3 (en) Imidazopyridine-azolidinones, preparation method thereof, pharmaceutical composition containing same and their use
DE3917233A1 (de) 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
WO2022020890A1 (fr) Traitement d'états vétérinaires associés à cd151
US20230365567A1 (en) Compounds
WO2022020887A1 (fr) Traitement de troubles liés à cd151
US20090030049A1 (en) Medicament for genital herpes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21848919

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06.07.2023)

122 Ep: pct application non-entry in european phase

Ref document number: 21848919

Country of ref document: EP

Kind code of ref document: A1